


Rho-kinase Inhibitors For Treatment Is The Latest Antiglaucoma Drugs Industry Trend

The Business Research Company's Antiglaucoma Drugs Market Report -Opportunities And Strategies - Global Forecast To 2030

LONDON, GREATER LONDON, UK, May 11, 2021 /EINPresswire.com/ --Ophthalmology drugs market manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. The Rho-kinase pathway is an integral part of cellular functions



such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. Rho-kinase inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Ripasudil hydrochloride hydrate in the form of eye drops is approved in Japan for the treatment of glaucoma and ocular hypertension. Netarsudil formulated as an ophthalmic solution is used to treat intraocular pressure in patients with openangle glaucoma.

The <u>antiglaucoma drug therapy market</u> consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in the eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and others. The market does not include the sale of biologics used for the treatment of glaucoma.

Read More On The Global Antiglaucoma Drugs Market Report: https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

The global antiglaucoma drugs market is expected to grow from \$5.76 billion in 2020 to \$6.47

billion in 2021 at a compound annual growth rate (CAGR) of 12.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach \$8.17 billion in 2025 at a CAGR of 6%.

Major players in the <u>anti-glaucoma drugs industry</u> are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare, and Johnson & Johnson.

The global antiglaucoma drugs market is segmented by product type into alpha agonist, beta blockers, prostaglandin analogs, combined medication, others, by disease condition type into open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, other types of glaucoma, and by type into hospital prescription drugs, over-the-counter drugs.

Antiglaucoma Drugs Market - By Product Type (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others), By Disease Condition Type (Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma), By Prescription Type (OTC Drugs, Prescription Drugs), And By Region, Opportunities And Strategies – Global Antiglaucoma Drugs Market Forecast To 2030 is one of a series of new reports from The Business Research Company that provides antiglaucoma drugs market overview, forecast antiglaucoma drugs market size and growth for the whole market, antiglaucoma drugs market segments, and geographies, antiglaucoma drugs market trends, antiglaucoma drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Antiglaucoma Drugs Market Report: <u>https://www.thebusinessresearchcompany.com/sample.aspx?id=3522&type=smp</u>

Here Is A List Of Similar Reports By The Business Research Company:

Ophthalmology Drugs Market - By Type (Antiglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030

https://www.thebusinessresearchcompany.com/report/ophthalmology-drugs-market

Vision Care Devices And Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030

https://www.thebusinessresearchcompany.com/report/vision-care-devices-and-equipmentglobal-market-report

Interested to know more about The Business Research Company?

Read more about us at <u>https://www.thebusinessresearchcompany.com/about-the-business-</u> research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase: Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/540509054

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.